Drug discovery and development – Page 34
-
-
OpinionNatural born chemists
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe
-
BusinessGSK to apply for malaria vaccine approval
Infection protection drops over time, but the firm will go ahead with regulatory submission
-
FeatureRe-arming the antibiotic arsenal
How can we make new antibiotics? Phillip Broadwith takes a look
-
CareersNon-profit pharma
Not-for-profit drug discovery is growing into a promising niche employment opportunity within the pharmaceutical industry. James Mitchell Crow investigates
-
BusinessService with a smile
Company profile: Charnwood Molecular is more than a run-of-the-mill contract synthesis provider
-
FeatureAnimal pharm
Making drugs to treat animals is potentially lucrative – but also difficult, as Clare Sansom discovers
-
News
Former student sues Harvard for $10 million
PhD chemist seeks damages in row over patent royalties
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
OpinionCompulsory licences: necessity or threat?
Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?
-
NewsAntibiotic resistance is a ‘ticking time bomb’
Efforts to tackle the threat will need new thinking, but their may be no easy solutions or short cuts to new drugs
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe
-
NewsPharmaSea to scour ocean depths for new drugs
Bioprospecting project will investigate marine organisms in the search for new antibiotics and central nervous system therapies
-
Business
Flu vaccine without the eggs approved
Flublok does not require flu virus or eggs for manufacture
-
Business
TB drug milestone for bedaquiline
First TB drug with a new mechanism of action for 40 years wins approval
-
FeatureMaking pain history
From ancient folk remedy to the wonder drug of the early industrial age and beyond. Mike Sutton traces the remarkable history of aspirin
-
Business
Return on drug R&D dropping
The pharma industry is getting less and less return on investment in R&D but trend seems to be bottoming out
-
Business
Drug R&D costs rising
Review from UK consultancy suggests ten-fold increase in per medicine R&D costs over last 30 years
-
CareersNobel signals for new drugs
Sarah Houlton talks to a company that’s capitalising on the chemistry of communication